

## BIOANALYTICAL CAPABILITIES

We use a wide range of bioanalytical methods within a variety of platforms to support our clients' therapeutic candidates from discovery R&D (Pre-IND) to preclinical bioanalysis.

## BIOANALYTICAL SERVICES

Large Molecules	Advanced Therapy	Small Molecules
<ul style="list-style-type: none"> <li>• mAbs</li> <li>• Bispecifics (BsAbs)</li> <li>• Tetra specific Abs</li> <li>• Nanobody</li> <li>• Vaccines</li> <li>• Fusion proteins</li> <li>• Recombinant proteins</li> <li>• Enzymes</li> <li>• ADCs</li> <li>• ASO</li> <li>• Oligo</li> </ul>	<ul style="list-style-type: none"> <li>• Gene therapy</li> <li>• Gene editing</li> <li>• Oncolytic virus</li> <li>• Stem cells</li> <li>• CART</li> </ul>	<ul style="list-style-type: none"> <li>• Novel chemicals</li> <li>• Metabolites</li> <li>• PK/TK</li> <li>• BE/BA</li> <li>• Oligonucleotide (siRNA, RNAi)</li> <li>• Custom assays</li> </ul>

## BIOMERE EXPERTISE

- Wide range of animal models including primates to provide complete multi-species bioanalysis services
- Over 30 years of experience in small and large molecule bioanalysis
- Method development and validation using relevant agency guidelines
- Rapid custom assay development and validation support from JOINN global bioanalytical sciences

## LARGE MOLECULES

mAbs, bispecific/tetra specific antibody, nanobodies, fusion proteins/recombinant proteins, polypeptide/hormones, ADCs, enzymes, vaccines and biosimilars

- **Instrumentation:** Spectramax m5, MSD SQ Multiplex 120, Li-cor Odyssey, ELISpot, and flow cytometry
- LBA-based ELISA/MSD/ADA, cell-based NAb, cytokine & biomarker, ELISpot method development (MD), transfer (MT), and validation (MV)
- PK/PD, PK/TK for large molecular drugs in biofluid and tissue
- Tissue distribution analysis for biologics
- Immunogenicity testing ADA, NAb, for preclinical samples
- Single/multiplex cytokine panels/biomarker analysis for preclinical studies (*human samples coming soon*)
- Hybrid LBA/LC-MS/MS assays
- Protein quantification and enzyme activity assays
- Assays for B-cell and T-cell immune response including ELISpot
- Receptor occupancy and ICS assays
- Custom assays

## ADVANCED THERAPY

Gene therapy, gene editing, oncolytic virus, CART and stem cells

- **Instrumentation:** Quant Studio 5 Real-Time PCR System, Spectramax m5, MSD SQ Multiplex 120, ELISpot, Li-cor Odyssey, and flow cytometry
- RNA and DNA extraction from biofluid and various tissues
- RT-qPCR method development and validation
- qPCR quantification of advanced therapeutics
- Biodistribution, PK/PD for gene and cell therapeutics
- Vector shedding assay for preclinical studies
- Preexisting antibody screening and NAb for various AAV stereotype
- Anti AAV binding antibody and NAb assay
- Measurement of vector genome copy numbers
- ELISpot assay
- Virus titers assays
- Custom assays



## SMALL MOLECULES

Includes new chemicals entities/metabolites, oligonucleotide (siRNA, RNAi), ADC/payload

**Platform:** API LC-MS/MS, ICP-MS, UPLC, HPLC

- Method development (MD), transfer (MT) and validation (MV) for biofluid and tissue bioanalysis
- *In vivo* PK screening/Polit PK
- PK/PD, PK/TK for preclinical
- Compound or metal tissue distributions
- Formulation analysis
- Exposure analysis
- Detection and qualification of trace metal/metals
- Bioequivalent (BE)/bioavailability (BA)
- Custom assays

## LEARN MORE

- **Website**  
[biomere.com/cro-expertise](http://biomere.com/cro-expertise)
- **Contact Information**  
[ahall@biomere.com](mailto:ahall@biomere.com)



Download our new white paper  
"Bioanalysis of Large Molecule Therapeutics".

© Biomere, 2021

## IT'S PERSONAL.

Driven to expedite your journey.



**"With high-end bioanalytical platforms and bioanalysis expertise, Biomere provides quality data. Our expeditious turnaround time advances our clients' therapeutics into the clinical stage supporting healthier lives for those who are waiting for therapies and cures. Delivering superior bioanalytical services is personal to us."**

**- Ben Wei, PhD, Head of Bioanalytical Sciences**